Dana-Farber Cancer Institute: Leukemia, Myeloid, Acute trials

The registry lists 20 Leukemia, Myeloid, Acute studies with Dana-Farber Cancer Institute as lead sponsor. 7 are open to participants now and 1 have results posted.

Phase 1 13Phase 2 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young AdultsNot yet recruitingNCT07516353Not applicable
• CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
• Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
• IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
• A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Feasibility Pilot Exploring Variability in Biomarkers and PROs in AMLCompletedNCT04908852
• LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLActive, not recruitingNCT03709758Phase 1
• Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLActive, not recruitingNCT02091245Phase 1
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
• Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNCT00251368Phase 1
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
• High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
• Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
• Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2